3,459 Shares in Insulet Co. (NASDAQ:PODD) Purchased by SGL Investment Advisors Inc.

SGL Investment Advisors Inc. acquired a new position in shares of Insulet Co. (NASDAQ:PODD - Free Report) during the 3rd quarter, according to its most recent 13F filing with the SEC. The fund acquired 3,459 shares of the medical instruments supplier's stock, valued at approximately $805,000.

Several other hedge funds and other institutional investors also recently bought and sold shares of the business. Integrated Wealth Concepts LLC raised its holdings in shares of Insulet by 1.7% during the third quarter. Integrated Wealth Concepts LLC now owns 2,561 shares of the medical instruments supplier's stock worth $596,000 after purchasing an additional 42 shares during the period. Glenmede Trust Co. NA lifted its holdings in Insulet by 2.3% in the third quarter. Glenmede Trust Co. NA now owns 2,080 shares of the medical instruments supplier's stock worth $484,000 after acquiring an additional 47 shares during the last quarter. Wedmont Private Capital lifted its holdings in Insulet by 3.5% in the third quarter. Wedmont Private Capital now owns 1,433 shares of the medical instruments supplier's stock worth $326,000 after acquiring an additional 48 shares during the last quarter. OVERSEA CHINESE BANKING Corp Ltd boosted its stake in Insulet by 4.7% in the third quarter. OVERSEA CHINESE BANKING Corp Ltd now owns 1,076 shares of the medical instruments supplier's stock valued at $250,000 after acquiring an additional 48 shares during the period. Finally, Blue Trust Inc. raised its position in shares of Insulet by 84.1% during the 3rd quarter. Blue Trust Inc. now owns 127 shares of the medical instruments supplier's stock worth $30,000 after purchasing an additional 58 shares during the period.

Wall Street Analysts Forecast Growth

Several research analysts have commented on the stock. Raymond James upped their target price on shares of Insulet from $213.00 to $260.00 and gave the stock an "outperform" rating in a research report on Monday, October 14th. Canaccord Genuity Group raised their target price on Insulet from $269.00 to $304.00 and gave the company a "buy" rating in a research report on Monday. Morgan Stanley boosted their price target on shares of Insulet from $234.00 to $317.00 and gave the stock an "overweight" rating in a research report on Monday, November 11th. Piper Sandler increased their price objective on shares of Insulet from $230.00 to $285.00 and gave the company an "overweight" rating in a report on Tuesday, September 17th. Finally, BTIG Research lifted their price target on Insulet from $260.00 to $270.00 and gave the company a "buy" rating in a research report on Friday, November 8th. Three equities research analysts have rated the stock with a hold rating and twelve have assigned a buy rating to the company. According to MarketBeat.com, Insulet presently has an average rating of "Moderate Buy" and a consensus price target of $255.60.

Insulet Stock Down 0.8 %

Shares of PODD traded down $2.12 during trading hours on Monday, hitting $265.47. 443,137 shares of the company were exchanged, compared to its average volume of 545,836. The firm's 50 day moving average is $247.48 and its 200-day moving average is $217.32. The company has a debt-to-equity ratio of 1.21, a quick ratio of 2.80 and a current ratio of 3.68. Insulet Co. has a 52 week low of $160.19 and a 52 week high of $279.40. The company has a market cap of $18.62 billion, a PE ratio of 45.46, a PEG ratio of 4.06 and a beta of 1.21.

Insulet Company Profile

Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. The company's Omnipod platform includes the Omnipod 5 Automated Insulin Delivery System (Omnipod 5) which includes a proprietary AID algorithm embedded in the Pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless bluetooth communication; Omnipod DASH that features a bluetooth enabled Pod that is controlled by a smartphone-like Personal Diabetes Manager with a color touch screen user interface; and Omnipod GO, a standalone, wearable, insulin delivery system that provides a fixed rate of continuous rapid-acting insulin for 72 hours.